|1.||Laufs, Ulrich: 6 articles (03/2014 - 03/2002)|
|2.||Liao, James K: 6 articles (05/2010 - 11/2002)|
|3.||Böhm, Michael: 5 articles (12/2006 - 03/2002)|
|4.||Johnson, David W: 4 articles (01/2014 - 01/2009)|
|5.||Pfefferkorn, Jeffrey A: 4 articles (05/2011 - 01/2008)|
|6.||Egashira, Kensuke: 4 articles (04/2010 - 11/2003)|
|7.||Nickenig, Georg: 4 articles (12/2006 - 06/2002)|
|8.||Lefer, David J: 4 articles (09/2006 - 04/2005)|
|9.||Chen, Hua: 3 articles (09/2015 - 07/2011)|
|10.||Beri, Abhimanyu: 3 articles (09/2015 - 01/2009)|
10/01/1992 - "A look back indicates that HMG-CoA reductase inhibitors, as a class, appear to be safe and effective for long term use and constitute a major drug addition for the control of hypercholesterolemia. "
03/10/1989 - "HMG CoA reductase inhibitors offer considerable promise in the therapy of patients with primary hypercholesterolemia. "
09/01/2010 - "Earlier studies showed that the 3-hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (statin drugs), which are widely used to treat hypercholesterolemia, possess other pleotropic activities. "
05/01/2009 - "In this study, we investigated the inhibitory effect of HMG-CoA reductase inhibitors, widely used for hypercholesterolemia, on H-Ras-induced invasion of MCF10A cells. "
09/01/1996 - "This study contradicts a prior clinical finding and suggests that HMG CoA reductase inhibitors are unlikely to reduce plasma Lp(a) levels even in the absence of hypercholesterolemia."
05/01/2002 - "Large prevention studies show HMG-CoA reductase inhibitors significantly decreased major coronary events in the elderly similar to that observed in the younger people, and were also effective in preventing ischemic stroke. "
10/01/2006 - "Studies have shown an association between HMG-CoA reductase inhibitors (statins) and improved stroke outcomes, possibly secondary to neuroprotective properties. "
11/01/2012 - "HMG-CoA reductase inhibitors (statins) are associated with improved stroke outcome. "
01/01/2005 - "Few large-scale studies have investigated the effect of HMG-CoA reductase inhibitors (statins) on stroke prevention in old individuals. "
01/01/2004 - "Nevertheless, the results of recent studies investigating the effect of HMG-CoA reductase inhibitors ('statins') on cardiovascular events strongly suggest a stroke-preventive effect."
|3.||Coronary Disease (Coronary Heart Disease)
12/01/2008 - "HMG CoA reductase inhibitors (statins) have been shown to be effective lipid lowering agents and are beneficial in the primary and secondary prevention of coronary heart disease. "
08/01/1999 - "HMG-CoA reductase inhibitors have been shown to be effective in primary and secondary prevention of coronary heart disease. "
05/01/1999 - "HMG-CoA reductase inhibitors (statins) are effective in primary and secondary prevention of coronary heart disease. "
02/15/2002 - "Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease."
01/01/2011 - "Several studies have shown that treatment with HMG-CoA reductase inhibitors (statins) can reduce coronary heart disease (CHD) rates. "
|4.||Cardiovascular Diseases (Cardiovascular Disease)
10/01/2014 - "HMG-CoA reductase inhibitors (statins) have been shown to improve cardiovascular (CV) outcomes in the general population as well as in patients with cardiovascular disease (CVD). "
04/01/2013 - "Evidence suggesting shared common risk factors and mirrored pathophysiology between cardiovascular disease and AMD led to the hypothesis that hydroxymethylglutaryl-CoA reductase inhibitors (statins) could be helpful in preventing AMD. "
01/01/2003 - "Recent large clinical trials have demonstrated that HMG-CoA reductase inhibitors, or statins, markedly reduce morbidity and mortality when used in the primary and secondary prevention of cardiovascular disease. "
01/01/2000 - "[HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]."
01/01/2015 - "HMG CoA reductase inhibitors (statins) are known to prevent cardiovascular disease and improve lipid profiles. "
05/01/1994 - "After reviewing the literature concerning the advisability and efficacy of dyslipidemia treatment in old age, the authors present their experience with the use of HMG CoA reductase inhibitors. "
06/24/2008 - "A review of the evidence from subgroup analysis of several landmark lipid-lowering trials supports treating dyslipidemia in mild to moderate CKD patients with HMG-CoA reductase inhibitors. "
01/01/2005 - "Several ongoing trials of various pharmacologic agents should help clarify the role of these agents alone and in combination with HMG-CoA reductase inhibitors in the management of diabetic dyslipidemia."
07/01/2014 - "HMG-CoA reductase inhibitors ("statins") are commonly prescribed for the treatment of dyslipidemia and prevention of any complications arising from this disease. "
06/01/2010 - "Lipid profiles were evaluated for 281 dyslipidemia patients treated with HMG-CoA reductase inhibitors (statins) for 2 years. "
|1.||Coenzyme A (CoA)
|4.||Fibric Acids (Fibrates)
|10.||3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
|3.||Transplantation (Transplant Recipients)
|4.||Intensive Care (Surgical Intensive Care)
|5.||Drug Therapy (Chemotherapy)